Pancreatic cancer drug market expected to double by 2025

Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and chemotherapies; thus, demand is high for safer, more-efficacious drugs, which will serve to drive the market.

ResearchAndMarkets  projects that the global pancreatic cancer therapy market is expected to reach $ 4,056.4 million in 2025 from $ 2,011.2 million in 2017. The market is estimated to expand with a compound annual growth rate (CAGR) of 8.1% from 2018-2025. The growth of the pancreatic cancer therapy market is primarily attributed to the increase in number of therapies launched in the market.

The development of new drugs is thus expected to drive the growth of pancreatic cancer therapy market. The report continued by saying: "However, these drugs travel throughout the body and thus can affect normal and healthy cells adversely. Blood-forming cells in the bone marrow, hair follicles and cell in the mouth, digestive tract, and reproductive system are likely to be affected by chemotherapeutic drugs. The current treatment options available for pancreatic cancer patients only help to extend the patients' lives by a few months.